Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, HER2-negative breast cancer.
|Videos|February 25, 2016
Pioneering Oncologist Provides an Overview of Advances in Cancer
Author(s)Maurie Markman, Vincent T. DeVita
Dr. Maurie Markman sits down with Dr. Vincent T. DeVita, one of the most influential researchers and physicians in the cancer care arena.
Advertisement
Dr. Maurie Markman sits down with Dr. Vincent T. DeVita, one of the most influential researchers and physicians in the cancer care arena.
Advertisement
Related to this article
A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.
Dr. Saum Ghodoussipour of Rutgers Cancer Institute answers top searched bladder cancer questions, from treatment and surgery side effects to sex and work.
Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
Dr. Morana Vojnic answers common questions about brain cancer, including diagnosis, tumor types, treatment effects, recurrence and life after treatment begins.
Dr. Jacqueline Barrientos shares how a targeted therapy, a determined care team and a stranger’s generosity gave a 72-year-old man with hairy cell leukemia and kidney failure a second chance.
Dr. Robert Kreitman explains how CD22-targeted CAR T could help heavily pretreated patients.
An expert at ESMO 2026 explains how liquid biopsy and ESR1 testing can help guide treatment for people with HR-positive metastatic breast cancer.
Advertisement
Advertisement
Trending on CURE
1
Precision Radiation Cuts 1-Year Pancreatic Cancer Recurrence to 20.2%
2
3 Prostate Cancer Results From ESMO 2026 Patients Should Know
3
Urologic Oncologist Answers Top Searched Questions in Bladder Cancer
4
The Breast Cancer Test Many Patients Don’t Know to Ask For
5